Century Therapeutics Conference Call Summary Company Overview - **Company Name**: Century Therapeutics (Ticker: IPSC) - **Industry**: Biotechnology, specifically focused on induced pluripotent stem cells (iPSCs) and cell therapies Key Points and Arguments Clinical Programs - **CNTY-101**: An NK cell-based therapy with a CD19 CAR, currently in clinical trials in the U.S. and EU, targeting autoimmune diseases [3][20] - **CNTY-308**: A preclinical program targeting B-cell-mediated diseases, expected to enter clinical trials mid-next year [4] - **Non-Immune Cell Program**: A highly anticipated program that is not disclosed for competitive reasons but is believed to have significant potential [4] Scientific Advancements - **Cell Foundry**: Century's capability to produce adult functional cells from iPSCs, including CD4 and CD8 T cells, which are crucial for treating B-cell malignancies and autoimmune diseases [5][6] - **Alloevasion Technology**: Century is a leader in immune evasion strategies, with advancements from alloevasion 1.0 to 5.0, allowing for better protection of allogeneic cells from the patient's immune system [6][7][9] Pipeline and Efficacy - **Efficacy of T Cells**: The company claims that their iPSC-derived T cells can perform comparably to autologous T cells, with the ability to engage targets and proliferate effectively [15][16] - **Long-term Durability**: The combination of CD4 and CD8 T cells enhances long-term durability and effectiveness in tumor control [17][18] Clinical Trials and Results - **Calypso Trial**: A company-sponsored trial for CNTY-101, allowing for re-dosing without lymphodepletion, showing promise in autoimmune diseases [20][21] - **B Cell Malignancy Trial**: Previous trials demonstrated deep and sustained B cell depletion, indicating the potential for effective treatment in autoimmune diseases [23][24] Financial and Operational Updates - **Cash Runway**: The company has extended its cash runway through 2027, allowing for continued development and data collection from ongoing trials [7] - **Restructuring**: A recent restructuring has focused the company on key assets and streamlined operations [7] Additional Important Information - **Cost-Effectiveness**: The company aims to produce therapies at costs comparable to antibody treatments, which could enhance accessibility [22] - **Safety Profile**: NK cell therapies are noted for their favorable safety profile compared to T cell therapies, which can have severe side effects [22] - **Future Directions**: The company is exploring the possibility of reducing or eliminating lymphodepletion in trial designs, which could further enhance treatment options [28][29] This summary encapsulates the key insights from the conference call, highlighting Century Therapeutics' innovative approaches in the biotechnology sector, particularly in cell therapy and immune evasion strategies.

PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced that Chad Cowan, Ph.D., Chief Scientific Officer of Century Therapeutics, will present at Chardan’s 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025, at 12:20 p.m. ET in New York, NY. A live webcast of the presentation will be available on the ...

Core Insights - Century Therapeutics is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies targeting autoimmune diseases and cancer [3]. Company Overview - Century Therapeutics (NASDAQ: IPSC) is in the clinical stage of developing a pipeline of iPSC-derived cell therapies [3]. - The company utilizes its iPSC cell foundry and a unique immune evasion engineering technology called Allo-Evasion™ to enhance its therapies [3]. - Century aims to create off-the-shelf cell therapies to improve patient access and offer advantages over existing cell therapies, thereby advancing treatment options [3]. Upcoming Events - Chad Cowan, Ph.D., Chief Scientific Officer of Century Therapeutics, will present at Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025, at 12:20 p.m. ET in New York, NY [1]. - A live webcast of the presentation will be available on the company's Investors page, with an archived replay accessible for at least 30 days [2].

Summary of Century Therapeutics Conference Call Company Overview - **Company**: Century Therapeutics - **Ticker**: IPSC (NASDAQ) - **Focus**: Development of next-generation allogeneic cell therapies from programmable induced pluripotent stem cells (iPSCs) for autoimmune diseases and cancer [1][2] Core Technology and Pipeline - **Core Technology**: AlloVision technology, which enables the engineering of iPSC-derived cell therapies [2][5] - **Key Programs**: - **Century 308**: CD19 targeting CD4/CD8 alpha-beta CARiT cell therapy, currently in IND-enabling studies for B-cell-mediated diseases [3][5] - **Century 101**: CAR INK therapy targeting CD19, currently in clinical trials for autoimmune diseases [18][19] Clinical Development and Milestones - **Cash Runway**: Estimated to extend into Q4 2027, covering key clinical milestones [5] - **Clinical Trials**: - **Century 101**: In two Phase I trials for systemic lupus erythematosus (SLE), lupus nephritis, myositis, and systemic sclerosis [18][19] - **Century 308**: Expected to enter the clinic next year [5][18] Market Opportunity - **Autoimmune Disease Market**: Significant unmet medical need with tens of thousands of addressable patients in the U.S. for B-cell-mediated diseases [20][21] - **CAR T Therapy Market**: Current approved CAR T therapies have close to $5 billion in worldwide sales, but access remains a challenge with fewer than 30% of eligible patients receiving treatment [11][20] AlloVision Technology - **Immune Evasion**: AlloVision technology involves genetic edits to enhance the persistence of allogeneic cells and reduce rejection by the immune system [6][7] - **Holistic Protection**: AlloVision 5.0 includes multiple genetic modifications to protect against various immune rejection mechanisms [8][9] Preclinical and Clinical Data - **Century 308**: Demonstrated comparable functionality to primary T cells in preclinical studies, including IL-2 secretion and tumor control in mouse models [13][17] - **Century 101**: Established a safe and well-tolerated dose with effective B-cell depletion observed in clinical trials [22][23] Conclusion - **Future Outlook**: Century Therapeutics aims to leverage its iPSC platform and AlloVision technology to create impactful therapies for patients with severe diseases, with a focus on delivering clinical data throughout 2025 [24]

Group 1 - Century Therapeutics, Inc. is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer [1][3] - The CEO, Brent Pfeiffenberger, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9-10, 2025, in New York [1] - The company aims to provide off-the-shelf cell therapies to enhance patient access and improve treatment outcomes in autoimmune disease and cancer care [3] Group 2 - An on-demand webcast of the company presentation will be available starting at 7:00 a.m. ET on September 5, 2025, on Century's website [2] - The webcast will be archived for at least 30 days for investor access [2] Group 3 - Century Therapeutics utilizes expertise in cellular reprogramming, genetic engineering, and manufacturing to develop its cell therapy pipeline [3] - The company is in the clinical stage and is committed to advancing the field of cell therapies [3]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40498 Century Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware ...

Introduction & Executive Summary [CEO's Strategic Overview](index=1&type=section&id=CEO's%20Strategic%20Overview) The CEO outlined strategic priorities to focus capital on transformative cell therapy candidates and accelerate key programs - Strategic focus on potentially transformational cell therapy candidates and technologies[3](index=3&type=chunk) - Continued clinical execution of **CNTY-101** in autoimmune disease and acceleration of core preclinical programs[3](index=3&type=chunk) - IND-enabling studies are underway for **CNTY-308**, with rapid progress toward drug candidacy for the non-immune cell program[3](index=3&type=chunk) - **Brent Pfeiffenberger**, CEO, assumed the role of Board Chair, succeeding Joe Jimenez[3](index=3&type=chunk) [Key Highlights](index=1&type=section&id=Key%20Highlights) Q2 2025 highlights include ongoing CNTY-101 patient dosing, CNTY-308's advancement, a CEO leadership change, and an extended cash runway - Patient dosing is ongoing in the **CALiPSO-1 trial** for CNTY-101, with clinical data expected by **year-end 2025**[4](index=4&type=chunk) - **CNTY-308**, a CAR-iT cell therapy, is now in IND-enabling studies and is expected to progress into the clinic in **2026**[4](index=4&type=chunk) - CEO **Brent Pfeiffenberger** has been appointed to Board Chair[4](index=4&type=chunk) - Cash runway has been extended into the **fourth quarter of 2027**[4](index=4&type=chunk) Pipeline and Program Updates [CNTY-101 in Autoimmune Diseases](index=2&type=section&id=CNTY-101%20in%20Autoimmune%20Diseases) The CALiPSO-1 trial for CNTY-101 is actively enrolling patients, with initial data expected by year-end 2025 - **CALiPSO-1 trial** for CNTY-101 is progressing with continued patient enrollment and clinical trial site activations; **two patients dosed**[7](index=7&type=chunk) - Clinical data for CNTY-101 in B-cell-mediated autoimmune diseases is on track to be reported by the **end of 2025**[7](index=7&type=chunk) - **CARAMEL IIT study** activated in July, with initial patient enrollment and dosing expected in **Q3 2025**[7](index=7&type=chunk) - Preclinical data presented at EULAR 2025 Congress demonstrated CNTY-101's ability to exhibit **B cell depletion**[7](index=7&type=chunk) [CNTY-308 and Other Preclinical Programs](index=2&type=section&id=CNTY-308%20and%20Other%20Preclinical%20Program) CNTY-308 has initiated IND-enabling studies for B-cell-mediated diseases, with clinical studies planned for 2026 - **CNTY-308** initiated Investigational New Drug (IND)-enabling studies for B-cell-mediated diseases; clinical studies planned for **2026**[7](index=7&type=chunk) - Rapid progress towards drug candidacy has been made for Century's first non-immune cell therapy program engineered with **Allo-Evasion™ 5.0**[7](index=7&type=chunk) - EULAR 2025 Congress presentation supported CNTY-308's ability to deliver rapid ablation of primary B cells and **Allo-Evasion™ 5.0's** protection from allogeneic immune cells[8](index=8&type=chunk) Corporate Updates [Leadership Changes](index=3&type=section&id=Leadership%20Changes) CEO Brent Pfeiffenberger was elected Board Chair, succeeding Joe Jimenez, who transitioned to a special advisor role - **Brent Pfeiffenberger**, PharmD, Chief Executive Officer, was unanimously elected to serve as Board Chair[12](index=12&type=chunk) - **Joe Jimenez**, who served as Board Chair since 2021, transitioned to a new role as a special advisor[12](index=12&type=chunk) [Cash Runway and Strategic Focus](index=3&type=section&id=Cash%20runway%20extended) The company extended its cash runway into Q4 2027 through a workforce reduction and strategic pipeline prioritization - Cash runway extended into the **fourth quarter of 2027**[12](index=12&type=chunk) - Extension achieved through a workforce reduction in July 2025 and prioritization of pipeline development for **CNTY-101**, **CNTY-308**, and the non-immune cell program[12](index=12&type=chunk) Summary of Financial Results [Cash Position](index=3&type=section&id=Cash%20Position) The company's cash, cash equivalents, and marketable securities totaled $158.5 million as of June 30, 2025 Cash Position (in millions) | Metric | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash, cash equivalents, and marketable securities | $158.5 | $220.1 | - The company estimates its cash, cash equivalents, and investments will support operations into the **fourth quarter of 2027**[11](index=11&type=chunk) [Operating Expenses](index=4&type=section&id=Operating%20Expenses) Operating expenses for Q2 2025 saw slight decreases in both R&D and G&A compared to the prior year period Operating Expenses (Three Months Ended June 30, in millions) | Expense Type | 2025 | 2024 | Change (YoY) | | :--- | :--- | :--- | :--- | | R&D Expenses | $26.9 | $27.2 | $(0.3) | | G&A Expenses | $7.8 | $8.3 | $(0.5) | - Decrease in R&D expenses primarily due to a reduction of personnel and manufacturing costs, offset by an increase in research and laboratory costs[14](index=14&type=chunk) [Net Income (Loss)](index=4&type=section&id=Net%20Income%20(Loss)) The company reported a net loss of $32.5 million for Q2 2025, a slight increase from the $31.2 million loss in Q2 2024 Net Income (Loss) (Three Months Ended June 30, in millions) | Metric | 2025 | 2024 | Change (YoY) | | :--- | :--- | :--- | :--- | | Net Loss | $(32.5) | $(31.2) | $(1.3) | About Century Therapeutics [Company Overview](index=4&type=section&id=Company%20Overview) Century Therapeutics is a clinical-stage biotechnology company developing iPSC-derived cell therapies for autoimmune diseases and cancer - Century Therapeutics is a clinical-stage biotechnology company developing **iPSC-derived cell therapies**[13](index=13&type=chunk) - The pipeline includes programs designed to address **autoimmune diseases and cancers**[13](index=13&type=chunk) - Commitment to developing **off-the-shelf cell therapies** to expand patient access and advance care[13](index=13&type=chunk) Forward-Looking Statements [Disclaimer and Risk Factors](index=5&type=section&id=Disclaimer%20and%20Risk%20Factors) This report contains forward-looking statements subject to significant risks and uncertainties that could cause actual results to differ - The press release contains forward-looking statements regarding clinical development plans and timelines[15](index=15&type=chunk) - These statements involve known and unknown risks, uncertainties, and other important factors that may cause actual results to differ materially[15](index=15&type=chunk) - The company does not plan to publicly update or revise any forward-looking statements unless required by applicable law[15](index=15&type=chunk) Financial Statements (Detailed) [Condensed Balance Sheets](index=6&type=section&id=Condensed%20Balance%20Sheets) Total assets decreased to $284.7 million while total liabilities fell significantly to $74.8 million as of June 30, 2025 Condensed Balance Sheet Highlights (in thousands) | Metric | June 30, 2025 | December 31, 2024 | Change (vs. Dec 31, 2024) | | :--- | :--- | :--- | :--- | | Cash and cash equivalents | $56,878 | $58,441 | $(1,563) | | Short-term investments | $98,965 | $130,851 | $(31,886) | | Total current assets | $160,169 | $194,051 | $(33,882) | | Long-term investments | $2,690 | $30,818 | $(28,128) | | Total assets | $284,692 | $353,216 | $(68,524) | | Deferred revenue, current | $- | $109,164 | $(109,164) | | Total current liabilities | $14,948 | $129,782 | $(114,834) | | Total liabilities | $74,794 | $191,854 | $(117,060) | | Total stockholders' equity | $209,898 | $161,362 | $48,536 | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20consolidated%20statements%20of%20operations) The company reported a net income of $44.0 million for the first six months of 2025, driven by significant collaboration revenue Condensed Consolidated Statements of Operations Highlights (in thousands, except per share amounts) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Collaboration Revenue | $- | $771 | $109,164 | $1,625 | | Research and development | $26,859 | $27,220 | $53,439 | $50,641 | | General and administrative | $7,805 | $8,306 | $16,212 | $17,052 | | Total operating expenses | $34,664 | $35,526 | $69,651 | $67,693 | | Net income (loss) | $(32,541) | $(31,207) | $44,019 | $(59,269) | | Net income (loss) per common share Basic | $(0.38) | $(0.38) | $0.51 | $(0.82) |

Core Insights - Century Therapeutics reported significant progress in its pipeline, focusing on cell therapy candidates for autoimmune diseases and cancer, with ongoing clinical trials and preclinical studies [2][5][6] Financial Results - As of June 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $158.5 million, down from $220.1 million at the end of 2024, with an estimated cash runway extending into the fourth quarter of 2027 [13][12] - Research and Development (R&D) expenses for Q2 2025 were $26.9 million, slightly lower than $27.2 million in Q2 2024, while General and Administrative (G&A) expenses decreased to $7.8 million from $8.3 million in the same period [13][20] - The net loss for Q2 2025 was $32.5 million, compared to a net loss of $31.2 million in Q2 2024 [13][20] Pipeline Development - CNTY-101 is currently in a Phase 1 trial (CALiPSO-1) for B-cell-mediated autoimmune diseases, with patient dosing ongoing and clinical data expected by year-end 2025 [5][6] - CNTY-308 is advancing through IND-enabling studies as a potential treatment for B-cell-mediated diseases, with plans to initiate clinical studies in 2026 [4][7] Corporate Updates - Brent Pfeiffenberger has been appointed as Board Chair, succeeding Joe Jimenez, who will continue as a special advisor [2][12] - The company has made strategic decisions to focus on high-potential programs, including a workforce reduction to align resources with its pipeline development activities [12][5]

Core Viewpoint - Century Therapeutics, Inc. has been upgraded to a Zacks Rank 1 (Strong Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of a company's shares, leading to buying or selling actions that affect stock prices [4]. Company Performance and Outlook - The recent upgrade for Century Therapeutics indicates a positive outlook for its earnings, suggesting potential buying pressure and an increase in stock price [3][5]. - Analysts have raised their earnings estimates for Century Therapeutics, with the Zacks Consensus Estimate increasing by 76.4% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions [10].

Core Viewpoint - Momentum investing focuses on "buying high and selling higher," contrasting with traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Strategy - Momentum investing can be risky as stocks may lose momentum if future growth does not justify high valuations [1] - Identifying the right entry point for fast-moving stocks is challenging, and traditional momentum parameters may not always be reliable [1] Group 2: Bargain Stocks and Screening - Investing in bargain stocks with recent price momentum may be a safer strategy [2] - The Zacks Momentum Style Score is useful for identifying strong momentum stocks, while the 'Fast-Paced Momentum at a Bargain' screen helps find attractively priced fast-moving stocks [2] Group 3: Century Therapeutics, Inc. (IPSC) Analysis - Century Therapeutics, Inc. (IPSC) shows a four-week price change of 2.9%, indicating growing investor interest [3] - IPSC has gained 11.1% over the past 12 weeks, demonstrating its ability to deliver positive returns over a longer timeframe [4] - The stock has a beta of 1.78, suggesting it moves 78% more than the market in either direction [4] Group 4: Valuation and Earnings Estimates - IPSC has a Momentum Score of B, indicating a favorable time to invest [5] - The stock has a Zacks Rank 2 (Buy) due to upward revisions in earnings estimates, which attract more investors [6] - IPSC is trading at a Price-to-Sales ratio of 0.45, suggesting it is undervalued at 45 cents for each dollar of sales [6] Group 5: Additional Investment Opportunities - Besides IPSC, there are other stocks that meet the 'Fast-Paced Momentum at a Bargain' criteria, presenting further investment opportunities [7] - Zacks offers over 45 Premium Screens tailored to different investing styles to help identify winning stock picks [8]